Remove Angina Remove Cholesterol Remove Coronary Artery Disease
article thumbnail

Polygenic risk score predicts all-cause death in East Asian patients with prior coronary artery disease

Frontiers in Cardiovascular Medicine

Introduction Coronary artery disease (CAD) is a highly heritable and multifactorial disease. Numerous genome-wide association studies (GWAS) facilitated the construction of polygenic risk scores (PRS) for predicting future incidence of CAD, however, exclusively in European populations.

article thumbnail

Lowering Atherosclerotic Cardiovascular Disease Events by Treating Residual Inflammatory Risk

DAIC

Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronary artery disease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3

article thumbnail

Does Erectile Dysfunction Improve After Bypass Surgery?

MIBHS

One of the most effective treatments for severe coronary artery disease, a type of cardiovascular disease, is coronary artery bypass grafting (CABG), a procedure designed to restore blood flow to the heart. But does coronary artery bypass surgery also improve erectile capacity?

article thumbnail

The three things that can go wrong with the heart

Dr. Sanjay Gupta

With time, fat and cholesterol can get trapped in the areas of wear and tear and cause plaque formation. Firstly the plaque may continue to build up and cause actually restrict blood from getting to the heart muscle and this often presents with symptoms of chest tightness on exertion or angina. The plaques can damage us in 2 ways.

article thumbnail

What Cardiometabolic Clinicians Can Be Thankful For This Year

Cardiometabolic Health Congress

Another promising advancement is MK-0616 , an oral PCSK9 inhibitor in Phase 3 trials, showing a significant reduction in LDL cholesterol, which provides a more convenient alternative to current injection-based therapies​. The trial highlights the importance of reevaluating and optimizing thrombolytic therapies for better patient outcomes.